Posted by Social Science Research Network
Pleading Standards: The Hidden Threat to Actavis Michael A. Carrier (Rutgers University)
Abstract: In FTC v. Actavis, the Supreme Court held that a brand drug company’s payment to a generic firm to settle patent litigation and delay entering the market could violate the antitrust laws.
Since the decision, the issue of the pleading requirements imposed on plaintiffs has slipped under the radar. Along those lines, it is concerning that courts recently have imposed unprecedented hurdles. For example, the court in In re Effexor XR Antitrust Litigation failed to credit allegations that a generic delayed entering the market because a brand promised not to introduce its own “authorized generic” that would have dramatically reduced the true generic’s revenues. The same judge, in In re Lipitor Antitrust Litigation, dismissed a complaint despite allegations that the generic delayed entry in return for the brand’s forgiveness of hundreds of millions of dollars in potential damages in separate litigation.
This Essay explains why the excessive pleading standards in Effexor and Lipitor are not consistent with Actavis or the leading caselaw on pleading. It discusses cases that apply a more justifiable analysis. And it concludes that the imposition of inappropriate pleading standards significantly weakens the antitrust analysis of potentially anticompetitive settlements.
Featured News
Redfin Settles $9.2M Commission Inflation Lawsuits
May 7, 2024 by
CPI
DOJ Supports Colorado’s Efforts to Block Kroger-Albertsons Merger
May 7, 2024 by
CPI
Japan Considers Regulation of AI Developers
May 7, 2024 by
CPI
European Commission Extends Decision Deadline for Ita-Lufthansa Merger
May 7, 2024 by
CPI
UK, US and Australia Sanction Senior Leader of LockBit Cybercrime Gang
May 7, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Economics of Criminal Antitrust
Apr 19, 2024 by
CPI
Navigating Economic Expert Work in Criminal Antitrust Litigation
Apr 19, 2024 by
CPI
The Increased Importance of Economics in Cartel Cases
Apr 19, 2024 by
CPI
A Law and Economics Analysis of the Antitrust Treatment of Physician Collective Price Agreements
Apr 19, 2024 by
CPI
Information Exchange In Criminal Antitrust Cases: How Economic Testimony Can Tip The Scales
Apr 19, 2024 by
CPI